Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA)
Although the clinical effects of attempted nonsurgical treatment of benign prostatic hyperplasia have been well documented, detailed histological evaluation of the effects of treatment appears to be limited. The effect of long‐term administration of an antiandrogen, chlormadinone acetate (CMA), on b...
Gespeichert in:
Veröffentlicht in: | The Prostate 1994-09, Vol.25 (3), p.147-155 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 155 |
---|---|
container_issue | 3 |
container_start_page | 147 |
container_title | The Prostate |
container_volume | 25 |
creator | Harada, Masaoki Kinoshita, Yuzo Moriyama, Masatoshi Kondo, Iichiro Nakahashi, Mitsuru Kumagai, Harumi Sasaki, Koichi Hosaka, Masahiko |
description | Although the clinical effects of attempted nonsurgical treatment of benign prostatic hyperplasia have been well documented, detailed histological evaluation of the effects of treatment appears to be limited. The effect of long‐term administration of an antiandrogen, chlormadinone acetate (CMA), on benign prostatic hyperplasia was evaluated with histological comparison of two biopsy specimens, one before treatment and one after treatment. Secretory epithelium showed obvious regressive changes with occasional basal cell prominence after CMA treatment. Stromal elements, however, did not show any marked changes, except for occasional edematous loosening. Scores of multiple epithelial parameters tended to be correlated with clinical improvement in urinary obstructive symptoms, especially in patients with predominant glandular hyperplasia. These results suggest that long‐term administration of the potent antiandrogen CMA to inhibit dihydrotestosterone‐receptor binding might be a useful therapeutic maneuver in patients with glandular hyperplasia, without any deterioration of the stromal component. © 1994 Wiley‐Liss, Inc. |
doi_str_mv | 10.1002/pros.2990250306 |
format | Article |
fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1002_pros_2990250306</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>PROS2990250306</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4706-5255307feb8661a876c346da96ed25e3bb8f082c9adf868198771ad48216fc183</originalsourceid><addsrcrecordid>eNqFkM1vEzEQxa2qqITCmROSDz2Uw7Zj7_pjxamKSoMU2qoFVeJizXq9qWG_ZG-B8NfjKFEQp55Gmnm_NzOPkLcMzhgAPx_DEM94WQIXkIM8IDMGpcoACnFIZsAVZAXL1UvyKsbvAIkBfkSOlOAglJ6RPwsfp6EdVt5iS91PbJ9w8kNPh4ZWrvernm5WTKlp6eN6dGFsMXqkU3A4uZpWa9oO_SqbXOgo1p3vk2HYe9jHdggd1r4fekfRuuTk6On888X71-RFg210b3b1mHz9ePllvsiWN1ef5hfLzBYKZCa4EDmoxlVaSoZaSZsXssZSupoLl1eVbkBzW2LdaKlZqZViWBeaM9lYpvNjcr71temRGFxjxuA7DGvDwGxCNJsPzb8QE_FuS4xPVefqvX6XWpqf7OYYU2xNwN76uJcVnEumN7IPW9kv37r1c1vN7d3N_X9HZFs65el-72kMP4xUuRLm4frK3H6bL2Fxf2cg_wsjCJ0L</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA)</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Harada, Masaoki ; Kinoshita, Yuzo ; Moriyama, Masatoshi ; Kondo, Iichiro ; Nakahashi, Mitsuru ; Kumagai, Harumi ; Sasaki, Koichi ; Hosaka, Masahiko</creator><creatorcontrib>Harada, Masaoki ; Kinoshita, Yuzo ; Moriyama, Masatoshi ; Kondo, Iichiro ; Nakahashi, Mitsuru ; Kumagai, Harumi ; Sasaki, Koichi ; Hosaka, Masahiko</creatorcontrib><description>Although the clinical effects of attempted nonsurgical treatment of benign prostatic hyperplasia have been well documented, detailed histological evaluation of the effects of treatment appears to be limited. The effect of long‐term administration of an antiandrogen, chlormadinone acetate (CMA), on benign prostatic hyperplasia was evaluated with histological comparison of two biopsy specimens, one before treatment and one after treatment. Secretory epithelium showed obvious regressive changes with occasional basal cell prominence after CMA treatment. Stromal elements, however, did not show any marked changes, except for occasional edematous loosening. Scores of multiple epithelial parameters tended to be correlated with clinical improvement in urinary obstructive symptoms, especially in patients with predominant glandular hyperplasia. These results suggest that long‐term administration of the potent antiandrogen CMA to inhibit dihydrotestosterone‐receptor binding might be a useful therapeutic maneuver in patients with glandular hyperplasia, without any deterioration of the stromal component. © 1994 Wiley‐Liss, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.2990250306</identifier><identifier>PMID: 7520578</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Aged ; benign prostatic hyperplasia ; Biological and medical sciences ; Biomarkers - analysis ; chlormadinone acetate ; Chlormadinone Acetate - administration & dosage ; Chlormadinone Acetate - therapeutic use ; Drug Administration Schedule ; histological effect ; Humans ; Immunohistochemistry ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Prostatic Hyperplasia - drug therapy ; Prostatic Hyperplasia - metabolism ; Prostatic Hyperplasia - pathology ; Urinary system</subject><ispartof>The Prostate, 1994-09, Vol.25 (3), p.147-155</ispartof><rights>Copyright © 1994 Wiley‐Liss, Inc., A Wiley Company</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4706-5255307feb8661a876c346da96ed25e3bb8f082c9adf868198771ad48216fc183</citedby><cites>FETCH-LOGICAL-c4706-5255307feb8661a876c346da96ed25e3bb8f082c9adf868198771ad48216fc183</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpros.2990250306$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpros.2990250306$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4226188$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7520578$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Harada, Masaoki</creatorcontrib><creatorcontrib>Kinoshita, Yuzo</creatorcontrib><creatorcontrib>Moriyama, Masatoshi</creatorcontrib><creatorcontrib>Kondo, Iichiro</creatorcontrib><creatorcontrib>Nakahashi, Mitsuru</creatorcontrib><creatorcontrib>Kumagai, Harumi</creatorcontrib><creatorcontrib>Sasaki, Koichi</creatorcontrib><creatorcontrib>Hosaka, Masahiko</creatorcontrib><title>Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA)</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>Although the clinical effects of attempted nonsurgical treatment of benign prostatic hyperplasia have been well documented, detailed histological evaluation of the effects of treatment appears to be limited. The effect of long‐term administration of an antiandrogen, chlormadinone acetate (CMA), on benign prostatic hyperplasia was evaluated with histological comparison of two biopsy specimens, one before treatment and one after treatment. Secretory epithelium showed obvious regressive changes with occasional basal cell prominence after CMA treatment. Stromal elements, however, did not show any marked changes, except for occasional edematous loosening. Scores of multiple epithelial parameters tended to be correlated with clinical improvement in urinary obstructive symptoms, especially in patients with predominant glandular hyperplasia. These results suggest that long‐term administration of the potent antiandrogen CMA to inhibit dihydrotestosterone‐receptor binding might be a useful therapeutic maneuver in patients with glandular hyperplasia, without any deterioration of the stromal component. © 1994 Wiley‐Liss, Inc.</description><subject>Aged</subject><subject>benign prostatic hyperplasia</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - analysis</subject><subject>chlormadinone acetate</subject><subject>Chlormadinone Acetate - administration & dosage</subject><subject>Chlormadinone Acetate - therapeutic use</subject><subject>Drug Administration Schedule</subject><subject>histological effect</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Prostatic Hyperplasia - drug therapy</subject><subject>Prostatic Hyperplasia - metabolism</subject><subject>Prostatic Hyperplasia - pathology</subject><subject>Urinary system</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM1vEzEQxa2qqITCmROSDz2Uw7Zj7_pjxamKSoMU2qoFVeJizXq9qWG_ZG-B8NfjKFEQp55Gmnm_NzOPkLcMzhgAPx_DEM94WQIXkIM8IDMGpcoACnFIZsAVZAXL1UvyKsbvAIkBfkSOlOAglJ6RPwsfp6EdVt5iS91PbJ9w8kNPh4ZWrvernm5WTKlp6eN6dGFsMXqkU3A4uZpWa9oO_SqbXOgo1p3vk2HYe9jHdggd1r4fekfRuuTk6On888X71-RFg210b3b1mHz9ePllvsiWN1ef5hfLzBYKZCa4EDmoxlVaSoZaSZsXssZSupoLl1eVbkBzW2LdaKlZqZViWBeaM9lYpvNjcr71temRGFxjxuA7DGvDwGxCNJsPzb8QE_FuS4xPVefqvX6XWpqf7OYYU2xNwN76uJcVnEumN7IPW9kv37r1c1vN7d3N_X9HZFs65el-72kMP4xUuRLm4frK3H6bL2Fxf2cg_wsjCJ0L</recordid><startdate>199409</startdate><enddate>199409</enddate><creator>Harada, Masaoki</creator><creator>Kinoshita, Yuzo</creator><creator>Moriyama, Masatoshi</creator><creator>Kondo, Iichiro</creator><creator>Nakahashi, Mitsuru</creator><creator>Kumagai, Harumi</creator><creator>Sasaki, Koichi</creator><creator>Hosaka, Masahiko</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>199409</creationdate><title>Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA)</title><author>Harada, Masaoki ; Kinoshita, Yuzo ; Moriyama, Masatoshi ; Kondo, Iichiro ; Nakahashi, Mitsuru ; Kumagai, Harumi ; Sasaki, Koichi ; Hosaka, Masahiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4706-5255307feb8661a876c346da96ed25e3bb8f082c9adf868198771ad48216fc183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Aged</topic><topic>benign prostatic hyperplasia</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - analysis</topic><topic>chlormadinone acetate</topic><topic>Chlormadinone Acetate - administration & dosage</topic><topic>Chlormadinone Acetate - therapeutic use</topic><topic>Drug Administration Schedule</topic><topic>histological effect</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Prostatic Hyperplasia - drug therapy</topic><topic>Prostatic Hyperplasia - metabolism</topic><topic>Prostatic Hyperplasia - pathology</topic><topic>Urinary system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Harada, Masaoki</creatorcontrib><creatorcontrib>Kinoshita, Yuzo</creatorcontrib><creatorcontrib>Moriyama, Masatoshi</creatorcontrib><creatorcontrib>Kondo, Iichiro</creatorcontrib><creatorcontrib>Nakahashi, Mitsuru</creatorcontrib><creatorcontrib>Kumagai, Harumi</creatorcontrib><creatorcontrib>Sasaki, Koichi</creatorcontrib><creatorcontrib>Hosaka, Masahiko</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harada, Masaoki</au><au>Kinoshita, Yuzo</au><au>Moriyama, Masatoshi</au><au>Kondo, Iichiro</au><au>Nakahashi, Mitsuru</au><au>Kumagai, Harumi</au><au>Sasaki, Koichi</au><au>Hosaka, Masahiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA)</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>1994-09</date><risdate>1994</risdate><volume>25</volume><issue>3</issue><spage>147</spage><epage>155</epage><pages>147-155</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>Although the clinical effects of attempted nonsurgical treatment of benign prostatic hyperplasia have been well documented, detailed histological evaluation of the effects of treatment appears to be limited. The effect of long‐term administration of an antiandrogen, chlormadinone acetate (CMA), on benign prostatic hyperplasia was evaluated with histological comparison of two biopsy specimens, one before treatment and one after treatment. Secretory epithelium showed obvious regressive changes with occasional basal cell prominence after CMA treatment. Stromal elements, however, did not show any marked changes, except for occasional edematous loosening. Scores of multiple epithelial parameters tended to be correlated with clinical improvement in urinary obstructive symptoms, especially in patients with predominant glandular hyperplasia. These results suggest that long‐term administration of the potent antiandrogen CMA to inhibit dihydrotestosterone‐receptor binding might be a useful therapeutic maneuver in patients with glandular hyperplasia, without any deterioration of the stromal component. © 1994 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>7520578</pmid><doi>10.1002/pros.2990250306</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0270-4137 |
ispartof | The Prostate, 1994-09, Vol.25 (3), p.147-155 |
issn | 0270-4137 1097-0045 |
language | eng |
recordid | cdi_crossref_primary_10_1002_pros_2990250306 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Aged benign prostatic hyperplasia Biological and medical sciences Biomarkers - analysis chlormadinone acetate Chlormadinone Acetate - administration & dosage Chlormadinone Acetate - therapeutic use Drug Administration Schedule histological effect Humans Immunohistochemistry Male Medical sciences Middle Aged Pharmacology. Drug treatments Prostatic Hyperplasia - drug therapy Prostatic Hyperplasia - metabolism Prostatic Hyperplasia - pathology Urinary system |
title | Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA) |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T02%3A33%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Histological%20evaluation%20of%20benign%20prostatic%20hyperplasia%20treated%20by%20long-term%20administration%20of%20chlormadinone%20acetate%20(CMA)&rft.jtitle=The%20Prostate&rft.au=Harada,%20Masaoki&rft.date=1994-09&rft.volume=25&rft.issue=3&rft.spage=147&rft.epage=155&rft.pages=147-155&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/pros.2990250306&rft_dat=%3Cwiley_cross%3EPROS2990250306%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/7520578&rfr_iscdi=true |